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Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for
many hematological malignant and non-malignant disorders. However, key obstacles
to the success of HCT include graft-versus-host disease (GVHD) and disease relapse
due to absence of graft-versus-tumor (GVT) effect. Over the last decade, advances in
“omics” technologies and systems biology analysis, have allowed for the discovery and
validation of blood biomarkers that can be used as diagnostic test and prognostic test
(that risk-stratify patients before disease occurrence) for acute and chronic GVHD and
recently GVT. There are also predictive biomarkers that categorize patients based on
their likely to respond to therapy. Newer mathematical analysis such as machine learning
is able to identify different predictors of GVHD using clinical characteristics pre-transplant
and possibly in the future combined with other biomarkers. Biomarkers are not only
useful to identify patients with higher risk of disease progression, but also help guide
treatment decisions and/or provide a basis for specific therapeutic interventions. This
review summarizes biomarkers definition, omics technologies, acute, chronic GVHD and
GVT biomarkers currently used in clinic or with potential as targets for existing or new
drugs focusing on novel published work.
Keywords: biomarkers, graft-versus-host disease, graft-versus-tumor, hematopoietic cell transplantation,
proteomics
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the most widely used
immunotherapy for the treatment of many hematologic disorders. While HCT induces beneficial
graft-versus-tumor (GVT), the development of graft-versus-host-disease (GVHD) remains a major
cause of mortality and morbidity in patients post-HCT. There are two main clinical presentations
of GVHD: acute GVHD (aGVHD) and chronic GVHD (cGVHD). aGVHD affects up to 50%
of allo-HCT recipients, and is characterized by an exacerbated inflammatory response and a
combination of signs and symptoms that target the skin, liver and the gastrointestinal track. The
clinical manifestation of aGVHD includes nausea, vomiting, anorexia, watery or bloody diarrhea
with crampy abdominal pain, maculopapular rash, and cholestatic liver disease (1, 2). On the other
hand, cGVHD develops in up to 70% of allo-HCT recipients and clinically involves a plethora
of organ systems including the oral, musculoskeletal, and genital, and is also similar to immune
diseases such as scleroderma. cGVHD is the most long-lasting complication of allo-HCT and results
in high non-relapse mortality (NRM) in up to 12% of cases, organ dysfunction, high morbidity, and
impaired quality of life (3–5). While HCT with HLA-matched unrelated donor, HCT with HLA-
mismatch related donor, older recipient and donor age, the use of female donor for male recipients
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are all risks factors associated with the development of cGVHD,
high grade aGVHD is associated with an increased risk of
cGVHD development in patients (6). Unfortunately, patients
at high risk of treatment unresponsiveness, GVHD morbidity,
or even death fail an early diagnosis due to the lack of early
prognostic tools that would enable to identification of patients
before disease onset.
Over the years, advances in bioinformatics including machine
learning, chemistry, engineering, and high-throughput technical
instruments have massively contributed to the development of
“omics” technologies. Using these tools, several novel specific and
sensitive blood based-biomarkers were identified and validated
in large patient’s cohort to aid in the diagnosis, prognosis,
risk prediction, and response to therapy of patients post-HCT.
These biomarkers can serve as potential therapeutic targets
for existing or novel drugs and also be exploited to facilitate
with the diagnosis and clinical assessment of disease severity
in patients to enable an optimal clinical management during
disease progression.
This review will summarize these novel drug-targetable
aGVHD, cGVHD and GVT biomarkers post-HCT identified
using a large number of patients (cutoff of at 50 patients per
cohort), a validation cohort, and validated at the protein level
with the potential for rapid translation into the clinic.
BIOMARKERS DEFINITIONS
The Working group on biomarkers for the National Institutes
of Health Consensus Development Project on Criteria for
Clinical Trials in Chronic Graft-versus-host disease (GVHD)
report and the North American and European Consortium
put forward a list of definitions for GVHD biomarkers (7, 8).
A biomarker mostly refers to a biochemical variable, such as a
circulating protein or a biomolecule and is categorized into four
major definitions:
(1) A diagnostic biomarker is used to identify GVHD patients
at the onset of the disease and aid to differentiate their
symptoms from other conditions.
(2) A prognostic biomarker is used to identify patients with
different degree of risk for GVHD occurrence, progression
or resolution before the onset the disease.
(3) A predictive biomarker categorizes patients based on their
likelihood to respond to therapy before GVHD therapy.
(4) A response to treatment biomarker aids monitor
patients’ response to treatment when pre-therapy sample
is collected.
BIOMARKER DEVELOPMENT PHASES
The development of biomarkers is complex and consists of
multiple phases, from candidate molecular targets to routine use
in the clinics. Prior to prospective studies, validation with both
training and verification cohorts, then validation in independent
cohorts must be conducted (7, 8). The different phases are
detailed below:
Discovery Phase
First, using a discovery phase small scale cohort of 20 to 40
cases and controls are compared using tools mentioned in
the next paragraph. Statistical analysis to evaluate the accuracy
of biomarkers relies on the AUC of ROC, which is one the
most objective biomarker performance evaluation. It measures
specificity on the x-axis versus 1 minus sensitivity on the y-axis
for every possible cut off (9). A biomarker can be evaluated using
the following guidelines: AUC of 0.9–1.0 = excellent; AUC of 0.8–
0.9 = good; AUC of 0.7–0.8 = fair; AUC of 0.6–0.7 = poor; and
AUC of 0.5–0.6 = fail (9). Candidate biomarkers with enough
specificity and sensitivity determined by an area under the curve
(AUC) of the receiver operating characteristic (ROC) >0.70, will
move forward to the next phase of qualification.
Qualification Phase
In the second phase, the few biomarkers that were selected in the
discovery phase are now evaluated with a qualified assay. An assay
is qualified using important analytical parameters such as the
specificity, accuracy, precision, robustness, limit of quantitation,
linearity, range, ruggedness and detection limit. It is important
to note that the finalized assay cannot be changed without
requalification of the assay under the revised conditions.
Validation Phase
The last phase will lead to the biomarker able to be used in a
clinical trial to test its impact on patient outcomes using the
qualified assay as described above (7, 8).
TOOLS USED IN THE IDENTIFICATION
OF BIOMARKERS
First, a note on samples to be collected, which should ideally be
non-invasive, and allowing for multiple time points collection.
Therefore, biofluids such as sera, plasma, and urine are highly
preferred. Furthermore, most repositories contain plasma and
sera because they are easy to process and store. Another non-
invasive sample is urine, but its protein composition is inherently
biased by renal filtration.
Over the last decades, advances in omics technologies have
allowed for the analysis of a broad spectrum of molecular changes
in a single cell or an organism to provide information regarding
a disease. Omics is defined as the complete sets of molecules,
including proteomics, cytomics, transcriptomics, and genomics
that were facilitated by engineering and provided increased
data throughput (10, 11). In the next section, the different
omics technologies used for the identification of biomarkers
will be discussed.
Profiling Using Genomics
Patients’ outcomes post-allo-HCT can be improved by
strategies that aim at (1) reducing peri-transplantation risk
and (2) facilitating diagnosis and prognosis of HCT-related
complications. Gene signatures were previously associated
with GVHD prevention and management. Single chain
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polymorphism (SNPs) are the most common types of naturally
occurring mutations in a population. In a retrospective study,
a total of 25 SNPs in 12 cytokine genes were evaluated in a
cohort of 509 HLA-identical sibling donor allo-HCT patients
for the prediction of aGVHD and cGVHD. Using a linear
regression model and the least absolute shrinkage and selection
operator (LASSO), SNPs combined with other clinical factors
could predict severe GVHD (12). Recently, a genome-wide
association studies (GWASs) of polymorphism showed that
although the number of minor HLA mismatches was double
in non-related transplants compared to sibling HLA-matched
transplants, GVHD outcomes were higher in HLA-DP GVHD-
mismatched unrelated recipients than in HLA-matched related
recipients, demonstrating that increased GVHD development
after unrelated-HCT is mostly due to HLA-mismatching (13).
Another GWAS study of 3,532 patients, known as the Discovery-
BMT study demonstrated the association with SNPs in the major
histocompatibility complex II and overall survival post HLA-
matched unrelated donor HCT (14). Functional single nucleotide
polymorphisms in the major histocompatibility complex II are
associated with overall survival after HLA matched unrelated
donor BMT). Unfortunately, large patients’ cohorts investigating
candidate-genetic polymorphism were unable to confirm
findings from a previous smaller cohort for both aGVHD
and cGVHD indicating that most published SNPs are not
reproducible because they were either non-functional or missing
important functional genetic elements (15, 16). However, in a
more recent study, donors SNPs of IL1RL1 exhibited a strong
correlation with pre-transplantation serum/plasma levels of
Stimulation-2 (ST2), which is also known as IL-33 receptor,
and an association with the risk of aGVHD and potential donor
selection implication (17).
Profiling Using Proteomics
Due to the complexity of data analysis and data acquisition,
the use of proteomics analysis is mostly limited to specialized
laboratories. Yet, the main advantage is that biomarkers
discovered through proteomics actually indicate the state of
the disease. GVHD biomarkers have been discovered using
proteomics analysis. Antibody arrays are quantitative and highly
sensitive for the detection of low-abundance proteins such
as cytokines. Their main limitation is the restricted number
of antibodies on the array, thus affecting the discovery of
candidate biomarkers. Another powerful tool for qualitative and
quantitative discovery of proteins in a complex protein mixture
is next generation mass spectrometry (MS), which uses a gel-
free separation method for the first step most likely liquid
chromatography, followed by MS. MS, particularly tandem MS
uses label-free methods or isotopically labeled tags for non-
ambiguous quantification. Proteins are identified from a mass
spectra matched to a sequence database (18). Although these
methods are the most efficient for biomarker discovery in
clinical research, these approaches are too time consuming to
use in validation.
Despite the great promise for biomarker discovery using
next-generation MS, they are limitations between biomarker
validation and discovery due to (1) the paucity of affinity-capture
reagents that has led to bias in the prioritization of candidate
biomarkers, and (2) the increase in the number of samples
necessary for validation that augments when a biomarker passes
to each test phase, thus creating the need for high-throughput
assays. Sandwich enzyme linked immunosorbent assay (ELISA)
is the most specific and reliable approach for the quantification
of individual proteins because this method is simple, very easy to
perform with high reproducibly (3).
Profiling Using Cytomics
Flow cytometry and mass cytometry are high-throughput
methods used for the profiling of immune cell populations.
CYTOF is a time-of-flight MS approach used for the
measurement of several markers on cells. This approach is
similar to flow cytometry, except for the use of heavy metals
ion tags labeled antibodies instead of fluorochromes. The
main advantage of CYTOF over flow cytometry is that more
antibody specificities can be used in a single sample (classically
30–40 antibodies), without significant spillover between
channels. Although CYTOF is limited to the markers used, this
technology and its software have enabled the discovery of new
cell populations such as regulatory T cells (Tregs) (19–22), B
cells (23, 24), T follicular helper (TFH) cells (25), T follicular
regulatory (TFR) (26) cells, and invariant natural killer T cells
(27), which will be discussed below. In addition, proteomics with
flow cytometry or mass cytometry enabled the discovery of a new
subset of T cells including the CD4+CD146+CCR5+ T cells in
aGVHD or cGVHD, and the blood mucosal-associated T cells
(CD161+TCRVα7.2+ and CD38+ T cells in cGVHD (28–30).
Although these set of immune cells provide great insight into the
pathophysiology of GVHD and are good therapeutic targets, they
remain less ideal biomarkers than soluble molecules measurable
by ELISA, due to the relatively low throughput associated with
cytomics, the lack of standard curve for quantification, and the
need for large samples of fresh blood. However, they remain best
markers of response to a specific treatment (e.g., Tregs, TFH
cells, and TFR cells post-IL2 therapy) (22, 26).
Profiling Using Transcriptomics
Transcriptomics refers to an organism’s transcriptome, or the
sum of all its RNA transcripts, including mRNAs, ln RNAs
and small RNAs (31). Studies of gene signatures of GVHD
can be classified as candidate-gene studies and genome-wide
studies, and also offer less bias in the identification of genes,
pathways, and gene expression networks active in the disease
(3). In the last years, transcriptomics analysis has led to major
discoveries in the fields of infectious disease, vaccinology, and
solid organ transplantation. Transcription analysis is mostly
performed using bulk peripheral blood mononuclear cells
(PBMCs), rather than whole-blood approaches as it limits
contamination by granulocytes. Although not independently
validated in a cohort, a classifier of 20 genes was discovered
in allo-HCT patients, and differentiates tolerant vs. non-
tolerant patients (32). In another multicenter study conducted
by Chronic Disease Consortium, an identifier of 3 different
RNA biomarkers genes, IRS2, PLEKHF1, and IL1R2, and two
variables (recipient cytomegalovirus serostatus and conditioning
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regimen intensity) accurately identified cGVHD patients from
controls (AUC = 0.81) (33). Although total mononuclear cells
can be utilized for transcriptomics and the identification of
biomarkers; this approach is not accurate as the largest cell
population, which is not reflective of the pathogenic cells, will
dominate. Therefore, specific subset of immune cell population
is sometimes used for RNA isolation. For instance, T cells, which
are associated with the pathogenicity of GVHD have been sorted,
then used for RNA isolation. Other novel identified drivers
of GVHD included programmed death ligand 1 (PD-L1) on
donor T cells, proinflammatory cytotoxic T cell 17 (Tc17), and
several other miRNAs (34–37). Using the highly translational
non-human primate (NHP) model, another group studied the
transcriptional signatures of T cells during breakthrough aGVHD
and hyperacute GVHD (38). They used sorted CD3+ T cells
in NHP and CD4+ and CD8+ T cells in humans in both
supervised and unsupervised gene expression analyses for the
identification of pathways controlling GVHD, and discovered
three transcriptional hallmarks of breakthrough aGVHD that are
not observed in hyperacute GVHD: (1) T cell persistence rather
than proliferation, (2) a highly inflammatory programming, (3) a
T helper (Th)/Tc1-mediated dysfunction driven by inflammatory
IL-17 dominated pathways (38). They further demonstrated the
role of Aurora Kinase A and the OX40:OX40L pathways as novel
mediators of aGVHD induced in both the NHP and human
alloreactive T cells that can be blocked with the combination
of mammalian target of rapamycin inhibition with sirolimus to
induce long-term control of both hyperacute and breakthrough
aGVHD (39, 40). More recently, monoprophylaxis with FR104,
an antagonistic CD28-specific pegylated-Fab’, or the combined
prophylaxis with sirolomus/FR104 enhanced the control of
effector T cell activation and proliferation to control GVHD in
NHPs (41). In circulating monocytes in cGVHD compared to
monocytes from normal subjects and non-cGVHD, two pathways
were upregulated: (1) interferon (IFN) inducible genes (MX1,
CXCL9, CXCL10) and innate receptors for cellular damage (Toll-
like receptor 7 and DDX58) (42).
Metabolic Biomarkers in GVHD
More recently, another study performed both global metabolic
analysis and transcriptomic profiling in two separate cohorts
of allo-HSCT recipients with or without aGVHD in order to
detect novel aGVHD biomarkers. Pathway analysis of 38 altered
metabolites and 1,148 differentially expressed gene surrogates
revealed a distinct glycerophospholipid metabolism signature of
aGVHD with predictive value (43). Although both a discovery
and validation cohort of 50 and 70 patients, respectively, were
used, this study has few limitations as (1) it has a relatively low
number of patients in each set that were selected to be positive
or negative not representing an all-comers population, and (2)
the biomarker validation at the protein level can more rapidly be
translated into a test for clinical application.
Analytical Tools
Beyond the classical statistics reviewed elsewhere (44), machine
learning methods are artificial intelligence tools stemming from
computer sciences that are used to learn information directly
from data without relying on a predetermined equation as a
model (45). One of the main advantages of this approach is
that it can process large amounts of data. In a retrospective
study of 28,236 HCT-patients from the European Blood and
Marrow Transplantation (EBMT) registry, 10/20 variables were
selected by the alternating decision tree (ADTree) model for
overall mortality at 100 days post-HCT which performed
better than the classical EBMT score (AUC of 0.701 vs.
0.646, p < 0.001) (46). Using the same algorithm, they
confirmed this finding in a smaller cohort of 1,848 patients
from the Italian Transplantation registry (GITMO) (AUC of
0.698 for day 100 mortality) (47). Furthermore, a recent study
from the Japanese Transplant Registry asked with similar
method (ADTree) if they would predict aGVHD grade II-IV
in a cohort of 26,695 HCT patients. Using 15/40 variables,
they predicted aGVHD grade II-IV with an AUC of 0.616.
The authors went on to validate these 15 variables with
conventional statistics and showed a cumulative incidence
of aGVHD II-IV of 58.9% with the high-risk score and
29% in the low risk score (48). This type of method can
also be used at a smaller scale to identify new features in
complex phenotypes such as cGVHD. For example, in one
study, the authors compared cause-specific hazard function to
the Bayesian Additive Regression Tree (BART) model in a
cohort of 845 patients with 427 cGVHD, and showed that
BART performed as well as cause-specific hazard function (49).
Another study with 339 patients with cGVHD features, revealed
that patients in the high- and intermediate-risk decision-tree
groups had significantly shorter survival than those in the low-
risk group (hazard ratio 2.74; 95% confidence interval: 1.58–
4.91 and hazard ratio 1.78; 95% confidence interval: 1.06–
3.01, respectively) (50). More recently, another study used
machine learning to assess the effects of immune parameters on
clinical outcomes after HLA-haploidentical and HLA-matched
allogeneic bone marrow transplantation with posttransplant
cyclophosphamide (PTCy). Findings showed that (1) NK cell
recovery can predict survival after both HLA-haploidentical
and HLA-matched HCT with PTCy, (2) early CD4+ T-cell
recovery and higher CXCL9 levels can predict development of
acute GVHD, and (3) high Reg3α levels at day 56 predict the
development of chronic GVHD, demonstrating that machine
learning can be utilized to demonstrate the association of
immune cell subsets and biomarkers with outcomes after HCT
(51). Machine learning has several strengths: (1) the model
handles a number of complexities in modeling, including
interactions, high-dimensional parameters. However, there are
two main weaknesses: (1) at the exception of tree algorithms,
it is not straightforward for the clinicians to directly interpret
the models by themselves (black box) and (2) it requires a large
sample size to train the model.
VALIDATED BIOMARKERS POST-HCT
Over the years, several biomarkers have been discovered and
validated in both aGVHD and cGVHD. According to the NIH
consensus on biomarkers, some proteins were moved from
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TABLE 1 | Plasma and cellular biomarkers for post-HCT outcomes.
Protein Study No. of patients in
the study
Association direction Diagnosis
timepoint
(median day
post-HCT)
Prognostic
timepoint
(median day
post-HCT)
References
Plasma aGVHD
4 biomarker panel:
IL-2-receptor-α, hepatocyte
growth factor (HGF), IL-8 tumor
necrosis factor receptor-1
Paczesny 2009 42+282†+142† Increased 28 ND 52
Interleukin-6 (IL-6) McDonald 2015 74†+76 † Increased 28 Not significant 53
Kennedy 2014 53 Increased (3–14), then
decreased
30 7–14 54
Stimulation 2 (ST2) Vander Lugt 2013 20+381†+673*+75* Increased 28 14 55
Levine 2015 328+164†+300† Increased 28 ND 56
Abu Zaid 2017 211 patients
(independent
cohort
post-validation)
Increased 28 ND 58
McDonald 2015 74†+76† Increased 28 Not significant 53
Hartwell 2017 620+309†+358† Increased ND 7 59
Major-Monfried 2018 236+142†129† Increased ND 7 64
McDonald 2017 165 Increased ND 14 65
T cell immunoglobulin domain
and mucin domain (TIM3)
McDonald 2015 74†+76†+167* Increased 28 14 53
Abu Zaid 2017 211 patients
(independent
cohort
post-validation)
Increased 28 ND 58
AREG/EGF ratio Holtan 2016 105+50† Increased 160 ND 66
Skin specific
Elafin Paczesny 2010 522+492† Increased 28 ND 67
Bruggen 2015 59 Increased 28 ND 68
Liver specific
REG3 α, HGF, and Keratin 18
(KRT18)
Harris 2012 954, 3 centers Increased 14 28 69
GI specific
Regenerating islet-derived 3-α
(REG3 α)
Ferrara 2011 20+871†143† Increased 28 ND 71
T cell immunoglobulin domain
and mucin domain (TIM3)
Hansen 2013 20+127†+22† Increased 28 ND 73
Cellular aGVHD
Regulatory T cells Magenau 2010 215 Decreased 3–14 28 19
CD146+ T cells Li 2016 20+214† Increased ND 14 28
CD30 Chen 2012 53 Increased ND ND 80
Chen 2017 34 Increased ND NA 81
Invariant natural killer T cells
(iNKT)
Chaidos 2012 57 Increased ND NA 82
Plasma chronic GVHD
sBAFF Sarantopoulos 2007 104 Increased 480 NA 93
Fujii 2008 80 Increased 171 (early&),
429 (late&)
NA 94
Kitko 2014 35+109†+211† Increased, and not
validated in
independent cohort
154+, 256
(early&), 619
(late&)
NA 95
Kariminia 2016 23+198†+83† Increased 203,174 NA 96
Saliba 2017 341 Increased/decreased # 189 NA 98
(Continued)
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TABLE 1 | Continued
Protein Study No. of patients in the
study
Association
direction
Diagnosis
timepoint
(median day
post-HCT)
Prognostic
timepoint
(median day
post-HCT)
References
CXCL9 Kitko 2014 35+109†+211† Increased 154+, 256 (early&),
619 (late&)
NA 95
Yu 2016 53+211†+180† Increased 210+,203& 100 99
Kariminia 2016 23+198†+83† Increased, and not
validated in
independent cohort
203+,174& NA 96
Hakim 2016 26+83† Increased 132 NA 42
Abu 2017 211 Increased NA 100, 180, 365
(time
dependent
analysis)
58
CXCL10 Kariminia 2016 23+198†+83† Increased 203+,174& NA 96
Hakim 2016 26+83† Increased 132 NA 42
Ahmed 2016 78+37 Increased 132 NA 97
Four protein panel (CXCL9,
ST2, OPN, MMP3)
Yu 2016 53+211†+180† Increased 210,203 100 99
MMP3 Liu 2016 76 (BOS) Increased 531 NA 100
CCL15 Du 2018 211†+792† Increased at onset,
but not prognostic
203 100 101
Cellular chronic GVHD
CD163 Inamoto 2017 40+127† Increased NA 80 102
B cells
TLR9+ She 2007 54 Increased 171 (early), 429
(late)
NA 103
CD21low Greinix 2008 70 Increased 1428 NA 104
Kuzmina 2013 136 Increased 143 NA 105
BAFF/B cell ratio Sarantopoulos 2009 57 Increased 180 NA 23
Tregs Zorn 2005 57 Decreased 720 NA 20
CD4+CD146+CCR5+ Forcade 2017 40 Increased 942 NA 29
TFH Forcade 2016 66 Decreased 867 NA 25
ND, not done; NA, not applicable; †Patient number in validation cohort 1 and cohort 2; +cohort 1 and &cohort 2.
candidate proteins to biomarkers (7). Those validated biomarkers
will be discussed in the section below and summarized in Table 1.
Acute GVHD Biomarkers
Plasma Biomarkers
Systemic biomarkers
A panel of 4 biomarkers: IL-2 receptor-α (IL-2Rα), tumor necrosis
factor receptor-1 (TNFR-1), IL-8, and hepatocyte growth factor
(HGF). Screening of aGVHD plasma samples using antibody
microarrays for 120 proteins and ELISA enabled for the discovery
and validation of the first panel of biomarkers consisting of a 4-
protein biomarker panel: IL-2Rα, TNFR-1, IL-8, and HGF. This
panel of biomarkers can confirm the diagnosis of aGVHD in
patients, and COX regression analysis revealed that the panel can
also predict survival independent of GVHD severity (52).
Interleukin-6 (IL-6). Interleukin-6 was identified as a predictive
biomarker for severe GVHD and NRM at both days 3 and 60
post-transplant in a cohort of 53 HCT patients. This finding was
then validated in a second cohort, where IL-6 was elevated at
the onset of GVHD (53). In a subsequent study, blockade of IL-
6 using tocilizumab in addition to standard GVHD prophylaxis
reduced the incidence of aGVHD (54).
Stimulation-2 (ST2). Stimulation-2, the IL-33 receptor or IL1RL1
gene product remains the most validated biomarker for aGVHD
and non-relapse mortality (NRM) either measured alone or
with other markers. (1) ST2 serves as a predictive biomarker.
ST2 was first identified in plasma obtained at a median
of 16 days after the initiation of aGVHD therapy in 10
patients with a complete response by day 28 post-therapy
initiation and compared to 10 patients with progressive aGVHD
during therapy. In that study, 12 biomarkers were compared,
and ST2 showed the highest association with resistance to
aGVHD and death without relapse. Patients with high ST2
levels had a higher risk to develop treatment resistant-
aGVHD compared to patients with low ST2 levels (55).
Additionally, ST2 could predict the development of aGVHD
independent of aGVHD grade (55). ST2 was subsequently
validated as a predictive biomarker in a larger cohort of 492
HCT patients with newly diagnosed GVHD. High ST2-based
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GVHD scores were associated with a lower response rate
to aGVHD treatment (56). Of note, the authors called this
a prognostic score when it was a predictive score. ST2 has
since been tested in a multi-center, open-label, randomized
clinical trial conducted by the Blood and Marrow Transplant
Clinical Trials Network (Study 1501, NCT02806947). This study
evaluated the difference in day 28 complete response (CR)
and partial response (PR) to sirolimus (steroid-free regimen)
as compared to prednisone as an initial treatment for patients
with Minnesota standard-risk and low-risk biomarker-confirmed
aGVHD. This study showed no difference in day 28 CR/PR
rates for sirolimus 64.8% (90% Cl 54, 1%–75.5%) compared
to 73% (90% Cl 63.8%–82.2%) for prednisone (57). This
shows that biomarker can aid clinicians opt for a lesser
toxic aGVHD regimen. (2) ST2 as a prognostic marker. ST2
levels in patients at day 14 post-HCT, prior to any clinical
manifestation of aGVHD, were associated with 6-month NRM
(55). Similar findings were made in several other studies
including a phase 3 multicenter study of 211 patients where
high ST2 at day 28 post-HCT were associated with 2 year-
NRM (58). In another study, a biomarker algorithm based
on ST2 plasma levels collected at day 7 post-HCT could
consistently predict the 6-month NRM in high risk (28%)
vs. low risk patients (7%), p < 0.001 (59). In a third
confirmatory study, plasma ST2 levels were also prognostic
for the development of aGVHD (53). We note that in this
study the authors use the term predictive instead of the
recommended prognostic term. Furthermore, the prognostic
value of ST2 has been shown in patients cohorts receiving
other HCT platforms such as HCT with non-myeloablative
conditioning regimen (60), cord blood HCT (single or double)
(61), HCT post cyclophosphamide as aGVHD prophylaxis
(62). In a contemporary multicenter center cohort of 415
patients (170 children ≤10 and 245 subjects >10 years (both
children and adults) recently published, landmark analyses
showed for the first time that pre-HCT high ST2 was
significantly associated with NRM particularly in children age
≤10 years [HR (CI): 4.82 (1.89–14.66), p = 0.0056 (63). (3)
Last, ST2 as a response to treatment marker. High ST2 and
Regenerating islet-derived 3-α (REG3α) when monitored as
early as 1 week after the initiation of treatment determined
the non-responder rates (64). Similar findings were reported
with the combination of ST2 and T-cell immunoglobulin
mucin-3 (TIM3) at 14 days post initiation of prednisone
(64, 65).
Amphiregulin (AREG)-to-epithelial growth factor (EGF) ratio. The
role of angiogenic factors in late aGVHD was tested by comparing
controls and cases aGVHD patients in a cohort of 105 patients,
then validated in a cohort of 37 cases. The authors found that
AREG-to-EGF ratio at or above median was associated with
lower overall survival and higher NRM in both cohorts. AREG-
to-EGF ratio was also elevated in classic aGVHD, but not in
cGVHD (66). This finding was not validated in an independent
cohort. However, the study showed that patients with aGVHD
and high AREG (≥33 pg/ml) had a lower response rate to steroid,
higher NRM, and lower overall survival (66).
Organ-specific biomarkers
Certain biomarkers are organ specific and enable the distinction
for instance from skin rashes and skin GVHD, or other forms of
enteritis to GI-GVHD. Target-specific aGVHD biomarkers are:
Skin specific Elafin. Elafin was also discovered using next-
generation proteomics and validated as both a diagnostic and
prognostic biomarker for skin GVHD, which is associated with
GVHD severity and NRM (67, 68).
Liver specific REG3α, HGF and cytokeratin-18-fragments
(KRT18). Regenerating islet-derived 3-α, HGF, and KRT18 were
elevated in patients with liver GVHD in a cohort of 954 patients
from three centers. It is important to note that REG3α had a
better AUC for the diagnosis of liver GVHD than HGF and
KRT18. However, this panel of liver GVHD specific biomarker
was not validated due to the low incidence of liver GVHD
(69, 70).
GI-Specific- Regenerating islet-derived 3-α (Reg3α) and T-cell
immunoglobulin mucin-3 (TIM3). T-cell immunoglobulin
mucin-3 and Reg3α are GI-GVHD specific biomarkers that
were identified and validated as prognostic biomarkers that can
identify patients at high risk for lethal aGVHD at day 7 and
day 14 for each, respectively (53, 59). Using next generation
proteomics, Reg3α and TIM3 were discovered at higher levels in
the lower GI of aGVHD. This finding was subsequently validated
in multiple cohorts either alone or in combination with other
markers (53, 69, 71–73).
Cellular Biomarkers
Regulatory T cells (Tregs)
CD4+CD25hiFoxp3+ Tregs showed both a diagnostic and
predictive value as a biomarker for aGVHD. Lower Tregs in the
peripheral blood of patients was associated with the development
of aGVHD. Furthermore, patients with Tregs frequencies
lower than the median exhibited higher NRM compared to
patients with Tregs higher than the median (19). This finding
was confirmed in another study where Tregs suppressed the
proliferative effects of conventional T cells, and promoted a
significant protection from lethal aGVHD (74). Furthermore,
Tregs were able to suppress the early expansion of alloreactive
donor cells, their IL-2R expression and their capacity to induce
aGVHD (75). One relevant study showed that the infusion of
ex vivo activated and expanded Tregs inhibited aGVHD lethality
(76). A more recent study showed that daily therapy with low
levels of interleukin-2 (IL-2) in patients improved CD4 Tregs-
suppressive function, and that better patients clinical response
seen with low dose IL-2 therapy was associated with an increased
diversity of the CD4 Tregs TCR repertoire in patients with
cGVHD (77). Please refer to the recent comprehensive review
that analyzes the role of T regs in both cGVHD and aGVHD (78).
CD4+CD146+CCR5+ T cells
Using in-depth, large-scale proteomic profiling of
presymptomatic samples, a T cell population expressing
CD146, an adhesion molecule, was found upregulated as early
as 14 days post-transplantation in patients with increased risk of
GI-GVHD. This population of T cells was also induced by ICOS
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stimulation. shRNA knockdown of CD146+ in T cells reduced
the infiltration of pathogenic TH17 cells to the gut, and increased
their survival and the frequency of Tregs (28).
CD30
Although not validated, CD30, a cell-surface protein found on
certain activated T cells, was highly expressed on the CD8+ T
cells or the plasma of aGVHD patients (79). In a subsequent
multicenter phase 1 clinical, brentuximab, an antibody-drug
conjugate targeting CD30, showed 38% response rate in steroid-
refractory GI-aGVHD patients (80).
Invariant natural killer T cells (iNKT cells)
High levels of iNKT cells in donor graft were associated
with a decrease in GVHD development. Patients that received
CD4−iNKT-cell doses above the median had a cumulative
incidence of grade II-IV of 24.2% compared to 71.4% in
patients with low iNKT-cell dose, p = 0.0008. This finding
was also not validated. The same finding was found in mixed
lymphocyte reaction assays where CD4−iNKT T cell suppressed
T cell proliferation and IFNγ secretion in a contact-dependent
manner (81).
Microbiota as a biomarker in GVHD
In early 1970s, studies in mice provided the first indication
that the intestinal microbiota affects the development of
GVHD when mice treated with antibiotics or germ-free mice
showed a prolonged survival post-allo HCT (82, 83). Then,
the use of high-throughput sequencing technologies provided
further information on the relevance of the microbiota in
GVHD, and specific information on the bacteria that might
be detrimental or beneficial post- HCT. The normal human
microbiota encompasses different anaerobic commensal bacteria,
mostly members of the Firmicutes and Bacteroidetes phyla (84–
86). However, during HCT, a dysbiosis or changes in the
microbiota are recorded. In two different studies, an increase in
Enterococcus and γ-Proteobacteria, including Enterobacteriaceae
were all associated with the development of GVHD and increased
mortality in patients post-transplantation (87, 88). On the other
hand, increased Bacteroides and Clostridium genus Blautia were
associated with lower GVHD in patients post-HCT. Another
study confirmed the loss of microbiota that occurs in the
gut post-HCT and found an increase in Lactobacillales and
a decrease in Clostridiales (89). Fecal metabolites can also
provide insightful information on GVHD patients’ outcome. For
instance, the presence of fecal butyrate and indole, in patients
post-HCT directly correlated with enrichment of Clostridiales
and Bacteriodales, respectively, in an analysis of 451 fecal
specimen from 44 patients before HCT through 100 days
post-HCT. Although fecal butyrate and indole did not impact
aGVHD incidence or overall survival in these patients, low levels
of butyrate were found in patients contracting blood stream
infections within 30 days (90).
Chronic GVHD Biomarkers
Chronic GVHD is a long-term complication that develops
in patients post blood or bone marrow transplantation
characterized by autoimmune disease-like symptoms such as
scleroderma and Sjogren syndrome. The clinical symptoms of
cGVHD include fibrosis and inflammation that affects multiple
organs and tissues within the body, thus making the diagnosis
of the disease challenging in patients (7, 9). Therefore, validated
cellular and plasma biomarkers would be beneficial for the
diagnosis, risk stratification and response to treatment in patients
post-HCT. Validated cGVHD plasma and cellular biomarkers are
listed in the next section.
Plasma Biomarkers
Soluble B-Cell activating factor (sBAFF)
Different studies demonstrated the role of sBAFF as both a
diagnostic and prognostic biomarker in chronic GVHD. High
sBAFF levels in patients were associated with active cGVHD
and both the early onset of GVHD (3–8 months) as well as late
cGVHD (≥9 months) (91–95). sBAFF can also predict response
to treatment as greater than a 50% decrease in sBAFF was
recorded in responders to corticosteroids at 2 months after the
initiation of therapy (92). In a more recent study, increased
sBAFF at the time of diagnosis were associated with NRM (96).
A panel of 4 biomarkers: ST2, CXCL9, Matrix
metalloproteinase 3 (MMP-3) and Osteopontin
A biomarker panel consisting of ST2, CXCL9, MMP-3,
and osteopontin was significantly correlated with cGVHD.
Furthermore, when measured at diagnosis or at day + 100 post-
transplantation, this panel allowed for patient risk stratification
according to cGVHD risk (97). MMP-3 was also associated
with the development of bronchiolitis obliterans (98). CXCL9 is
an interferon-γ-inducible ligand for chemokine (C-X-C motif)
receptor 3 (CXCR3), which is expressed on effector CD4 Th1
cells and CD8 cytotoxic T lymphocytes. Several studies showed
the upregulation of CXCL9 in cGVHD patients and correlation
with GVHD severity (42, 58, 93, 94, 97). Similarly, CXCL10,
an inflammatory chemokine that also binds to CXCR3 and is
involved with the activation, and recruitment of T cells, NK cells,
eosinophils, and monocytes, was also shown to be elevated in
cGVHD patients (42, 94). Recently, both CXCL9 and CXCL10
were elevated in cGVHD diagnosis in the first replication cohort,
but only CXCL10 in the second (94). In a different study,
the upregulation of both CXCL9 and CXCL10 in cGVHD was
confirmed using ELISAs (42), and therefore the importance
of CXCL9 and CXCL10 in the diagnosis of cGVHD needs to
further be evaluated.
CCL15
Using a tandem mass spectrometry proteomics analysis using
a multiorgan cGVHD model, CCL15, the human homolog of
CCL9, was identified as a novel cGVHD biomarker in a cohort
of 211 patients. In addition, patients with higher than median
levels of CCL15 showed a higher risk of NRM, demonstrating
that biomarkers identified through murine proteomics can also
enable for the discovery of novel biomarkers in patients (99).
CD163
CD163 is a macrophage scavenger receptor that is elevated during
oxidative stress. High plasma concentrations of CD163 have been
associated with the de novo onset of cGVHD. Patients with
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plasma soluble CD163 concentration at day 80 had a cumulative
incidence of de novo-onset of cGVHD of 75% vs. 40%, p = 0.018,
in patients with lower concentration of CD163 (100).
Cellular Biomarkers
B cells
Toll-like receptor 9 (TLR9) expressing B cells have been
associated with the development of cGVHD in patients
post-transplantation (101). Immature B cells, defined as
CD19+/CD21− cells in patients has also been associated with the
development of cGVHD (102, 103). Last, high plasma levels of
BAFF/B cell ratio was found in cGVHD patients compared to
healthy patients (23).
Tregs
Tregs were significantly reduced in cGVHD patients, where they
are essential for tolerance in cGVHD post-transplantation. In one
study, Tregs were evaluated in 57 patients post-HCT, and findings
showed that a decrease in CD4+CD25+T cells in patients with
cGVHD compared to patients without cGVHD (p = 0.009) (20).
In another study, an increase Th17/Treg ratio resulted in chronic
liver GVHD (104).
CD4+CD146+CCR5+ T cells
A novel subset of CD4+ CD146+ CCR5+ T cells, a TH-17
prone subset of CD4+ T cells was highly expressed in cGVHD
patients and sensitive to pharmacological inhibition. In a murine
model, donor T cells obtained from CD146-deficient mice had
significantly reduced pulmonary cGVHD compared to the wild-
type mice. Moreover, the CD146-deficient mice had significantly
lower pulmonary macrophage infiltration and T cell CCR5, IL-17,
and IFN-γ coexpression (29).
T follicular helper cells (TFH)
Lower circulating TFH (cTFH) cells have been found in patients
with active cGVHD compared to patients without cGHVD.
Findings also demonstrated that cTFH are activated and exhibit
a Th2/Th17 phenotype that promotes B-cell help function during
cGVHD (25).
Graft-Versus-Tumor (GVT) Biomarkers
In tumor immunotherapy, allo-HCT with donor lymphocyte
injection (DLI) promotes tumor cell killing through the GVT
effect. However, often times, the GVT effect is limited by the
development of aGVHD. Therefore, plasma biomarkers that can
distinguish GVT without GVHD would be beneficial. Recently,
plasma proteomics and systems biology analyses were conducted
on patients who experienced GVT and aGVHD compared to the
proteome of patients who experienced GVT without aGVHD.
The authors identified a total of 76 proteins that were associated
with GVT without GVHD. Additionally, an unique 61-protein
signature was also identified in patients with GVT without
GVHD. 43 genes of the 61 genes in the protein signature were
further confirmed using single-cell RNA sequencing analysis.
More importantly, few potential GVT biomarkers such as RPL23,
ILF2, CD58, and CRTAM were identified in GVT without GVHD
(105). These GVHD-free GVT biomarkers warrant further
analysis and validation in other cohorts.
PATHOGENIC AND DRUGGABLE
BIOMARKERS
Biomarkers than can provide insight in the pathogenesis of a
disease are even more relevant. For instance, during aGVHD,
intestinal stromal cells and intestinal T cells, producers of IFNγ
and IL-17, are both sources of sST2, a decoy for IL33. This limits
the availability of IL33 to cytoprotective T cells that express the
transmembrane form of ST2, which consist mostly of T helper 2
(Th2) cells and ST2+ Tregs (106). REG3α is a similar biomarker
that can prevent crypt apoptosis and aGVHD (107).
Another important characteristic of a biomarker is its
ability to be targeted with therapeutic drugs. In rheumatologic
diseases, cytokines have been identified as markers and targeted
with Janus Kinase (JAK) inhibitors either directly or via
intracellular signaling (108). This is also the case in cancer,
where signal transducer and activation of transcription 3
(STAT3) is a great potential therapeutic candidate that has
been targeted using a small-molecule degrader for complete
tumor regression (109). Similar drug targetable biomarkers in
GVHD would be very beneficial as these would target the
specific biomarker to reduce GVHD, promote therapy, and lower
toxicity. In aGVHD, peritransplantation blockade of sST2 using
a neutralizing monoclonal antibody or small molecule inhibitors
in a murine aGVHD model significantly reduces disease severity
and mortality, as well at increase plasma levels of IL-33, lower
the donor T cell infiltration to the gut, and IFNγ-producing T
cells, while increasing cytoprotective ST2 expressing T cells (106,
110). The adoptive transfer of mST2+ cells such as Tregs, IL-9-
expressing T cells, and innate lymphoid cells showed the same
effect. This is currently being evaluated in clinical trials (111, 112).
APPLICATIONS AND LIMITATIONS OF
BIOMARKERS IN CLINICAL PRACTICE
Many specific and sensitive biomarkers for both aGVHD and
cGVHD have been identified over the past decades. While these
biomarkers can be exploited for patient-risk stratification, early
GVHD assessment, monitoring of GVHD progression and for
cost-effective management decision-making, no biomarkers are
widely used in clinic. One of the main limitations for the
application of biomarkers in clinics has been the lack of an
adequate number of multicenter clinical trials. All candidate
biomarkers require to be thoroughly validated from preclinical
investigation to independent clinical research in large multicenter
cohort setting(s) (9). In addition, it is important to minimize
confounding variables or potential variables during studies by
acquiring high-quality bio-samples that are selected, stored and
processed rigorously. Last, collaboration between scientists and
clinicians are encouraged to validate GVHD biomarkers from the
bench for clinical use.
CONCLUSION
Advances in technology in the field of omics have permitted
the discovery of numerous biomarkers for identification of
complications post-HCT and signature of the beneficial GVT.
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A good biomarker has several features: has been developed
through the different phases including discovery and validation
in large independent cohorts, use a cost efficient non-invasive
robust assay that has been qualified. If, in addition the biomarker
is mechanistic, the likelihood of this biomarker to be relevant is
increased as for example ST2 that has been shown to be secreted
by IFNγ producing T cells. If the biomarker is involved in the
pathogenesis of the disease, it is likely that drugs (antibodies
or small molecules) could target the pathway involved. Future
directions should include aGVHD biomarkers preemptive trials.
Biomarkers for other diseases such as autoimmunity should
follow the same criteria.
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